Peer-influenced content. Sources you trust. No registration required. This is HCN.

Renal & Urology NewsDefinitive Local Therapy Improves Survival in Advanced Prostate Cancer

In a study of men with cT4 prostate cancer, definitive local treatment of the primary tumor site was associated with improved castration resistance-free survival.

A recent study has shed light on the potential benefits of definitive local therapy in improving survival outcomes for patients with cT4 prostate cancer. The findings, which are based on a retrospective study of 154 patients, suggest that this approach could be a game-changer in the treatment of advanced prostate cancer.

HCN Medical Memo
As healthcare professionals, these findings present us with a new perspective on treating advanced prostate cancer. The significant improvement in survival rates associated with definitive local therapy underscores its potential as a viable treatment option. This could lead to a paradigm shift in our approach to managing this disease, ultimately improving patient care and outcomes.

Key Points

  • The study was conducted by Chad Tang, MD, MS, of The University of Texas MD Anderson Cancer Center in Houston, and colleagues.
  • The patient cohort was heterogeneous with 54% having metastatic cT4N0-1M1 disease; 24% had regionally advanced cT4N1M0; and 22% had localized cT4N0M0.
  • Definitive local therapy was associated with significantly improved 5-year overall survival rates: 57% vs 31% without local therapy.
  • Sensitivity analyses revealed significantly higher local recurrence-free survival rates (76% vs 58%), castration resistance-free survival rates (58% vs 40%), and disease-free survival rates (45% vs 29%).
  • Definitive local therapy was associated with a 42% lower risk for all-cause mortality in the overall cohort.

For men with advanced prostate cancer, the survival rates significantly decrease. Specifically, for those with distant spread of prostate cancer, the average five-year survival rate is approximately 28-32%. This is much lower than the survival rates for local and regional stages of prostate cancer.

More in Urology

The Healthcare Communications Network is owned and operated by IQVIA Inc.

Click below to leave this site and continue to IQVIA’s Privacy Choices form